Company intelligence / Profile preview

ARBH

Cambridge, Massachusetts, United Statesarbhorses.com ↗

Ownership: Private
Development stage: Other

Overview

Arbor Biotechnologies is developing novel gene-editing treatments using a diverse toolbox of next-generation programmable DNA editors. The company aims to enable curative outcomes for patients with genetic diseases. Specific clinical results are not publicly disclosed as of now, suggesting programs are preclinical or early-stage.

Therapeutic areas: Rare Diseases
Modalities: Gene therapyGenome editing
Industry: Biotech

Beyond the preview

Go deeper on ARBH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARBH.

Explore the full profile